{
    "clinical_study": {
        "@rank": "36969", 
        "acronym": "PorticoALTEU", 
        "arm_group": {
            "arm_group_label": "Portico Transcatheter Aortic Valve Implantation", 
            "arm_group_type": "Experimental", 
            "description": "Placement of the SJM Portico aortic valve with a ALC delivery system"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this clinical investigation is to evaluate the use of the Portico ALC\n      Delivery System to place a transcatheter aortic valve through an alternative access site,\n      specifically subclavian/axillary or TAo."
        }, 
        "brief_title": "Assessment of the St. Jude Medical PorticoTM Re-sheathable Aortic Valve System - Alternative Access", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Symptomatic Aortic Stenosis", 
        "condition_browse": {
            "mesh_term": "Aortic Valve Stenosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has provided written informed consent.\n\n          -  Subject is 65 years of age or older at the time of index procedure, and/or has\n             comorbidities that, in the opinion of the Principal Investigator or the Subject\n             Selection Committee, preclude surgical valve replacement.\n\n          -  Subject's aortic annulus diameter meets the range indicated in the Instructions for\n             Use as measured by multislice CT conducted within 120 days prior to the index\n             procedure.\n\n          -  Subject has senile degenerative aortic stenosis with echocardiography within 30 days\n             of index procedure as defined by at least 1 of the following:\n\n               -  derived mean gradient greater than 40 mmHg, OR\n\n               -  jet velocity greater than 4.0 m/s, OR\n\n               -  aortic valve area of less than 0.8 cm2, OR\n\n               -  aortic valve area index less than or equal to 0.6 cm2/m2.\n\n          -  Subject has symptomatic aortic stenosis as demonstrated by NYHA Functional\n             Classification of II, III, or IV.\n\n          -  Subject is deemed high operable risk and delivery route is suitable for TAVI per the\n             medical opinion of the Subject Selection Committee.\n\n          -  Subject's predicted operative mortality or serious, irreversible morbidity risk is\n             less than 50% at 30 days post index procedure.\n\n        Exclusion Criteria:\n\n          -  Subject is unwilling or unable to comply with all study-required follow-up\n             evaluations.\n\n          -  Subject has a documented history of a cerebral vascular accident (CVA) or transient\n             ischemic attack (TIA) within 6 months (less than or equal to 180 days) prior to the\n             index procedure.\n\n          -  Subject has carotid artery disease requiring intervention.\n\n          -  Evidence of an acute myocardial infarction (MI) within 30 days prior to patient\n             providing consent (defined as: ST Segment Elevation as evidenced on 12 Lead ECG).\n\n          -  Subject has a native aortic valve that is congenitally unicuspid, bicuspid,\n             quadricuspid or non-calcified as seen by echocardiography.\n\n          -  Subject has mitral valvular regurgitation greater than grade III.\n\n          -  Subject has moderate or severe mitral stenosis.\n\n          -  Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in\n             any position.\n\n          -  Subject refuses any blood product transfusion.\n\n          -  Subject refuses surgical valve replacement.\n\n          -  Subject has left ventricular ejection fraction (LVEF) less than 20%.\n\n          -  Subject has documented, untreated symptomatic coronary artery disease (CAD) requiring\n             revascularization.\n\n          -  Subject has had a percutaneous interventional or other invasive cardiovascular or\n             peripheral vascular procedure less than or equal to 14 days of index procedure.\n\n          -  Subject has severe basal septal hypertrophy that would interfere with transcatheter\n             aortic valve placement.\n\n          -  Subject has a history of, or is currently diagnosed with endocarditis.\n\n          -  There is imaging evidence of intracardiac mass, thrombus, or vegetation.\n\n          -  Subject is considered hemodynamically unstable (requiring inotropic support or\n             mechanical heart assistance).\n\n          -  Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to\n             stabilize heart failure.\n\n          -  Subject with significant pulmonary disease as determined and documented by the\n             Investigator.\n\n          -  Subject has significant chronic steroid use as determined and documented by the\n             Investigator.\n\n          -  Subject has a documented hypersensitivity or contraindication to anticoagulant or\n             antiplatelet medication.\n\n          -  Subject has renal insufficiency as evidenced by a serum creatinine greater than 3.0\n             mg/dL (265.5 \u00b5mol/L) or end-stage renal disease requiring chronic dialysis.\n\n          -  Subject has morbid obesity defined as a BMI greater than or equal to 40.\n\n          -  Subject has ongoing infection or sepsis.\n\n          -  Subject has blood dyscrasias (eg, leukopenia, acute anemia, thrombocytopenia, history\n             of bleeding diathesis, or coagulopathy).\n\n          -  Subject has a current autoimmune disease that, in the opinion of the Principal\n             Investigator or the Subject Selection Committee, precludes the subject from study\n             participation.\n\n          -  Significant ascending aortic disease documented by diameter greater than 40mm.\n\n          -  Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within\n             90 days prior to the index procedure.\n\n          -  Subject is currently participating in another investigational drug or device study.\n\n          -  Subject requires emergency surgery for any reason.\n\n          -  Subject has a life expectancy less than 12 months.\n\n          -  Subject has other medical, social or psychological conditions that, in the opinion of\n             the Principal Investigator or the Subject Selection Committee, preclude the subject\n             from study participation.\n\n          -  Subject is diagnosed with dementia or admitted to a chronic care facility which would\n             fundamentally complicate rehabilitation from the procedure or compliance with\n             follow-up visits.\n\n          -  Subject is unwilling or unable to comply with all study-required follow-up\n             evaluations.\n\n          -  Subject has a documented history of a cerebral vascular accident (CVA) or transient\n             ischemic attack (TIA) within 6 months (less than or equal to 180 days) prior to the\n             index procedure.\n\n          -  Subject has carotid artery disease requiring intervention.\n\n          -  Evidence of an acute myocardial infarction (MI) within 30 days prior to patient\n             providing consent (defined as: ST Segment Elevation as evidenced on 12 Lead ECG).\n\n          -  Subject has a native aortic valve that is congenitally unicuspid, bicuspid,\n             quadricuspid or non-calcified as seen by echocardiography.\n\n          -  Subject has mitral valvular regurgitation greater than grade III.\n\n          -  Subject has moderate or severe mitral stenosis.\n\n          -  Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in\n             any position.\n\n          -  Subject refuses any blood product transfusion.\n\n          -  Subject refuses surgical valve replacement.\n\n          -  Subject has left ventricular ejection fraction (LVEF) less than 20%.\n\n          -  Subject has documented, untreated symptomatic coronary artery disease (CAD) requiring\n             revascularization.\n\n          -  Cardiovascular or peripheral vascular procedure less than or equal to 14 days of\n             index procedure.\n\n          -  Subject has severe basal septal hypertrophy that would interfere with transcatheter\n             aortic valve placement.\n\n          -  Subject has a history of, or is currently diagnosed with endocarditis.\n\n          -  There is imaging evidence of intracardiac mass, thrombus, or vegetation.\n\n          -  Subject is considered hemodynamically unstable (requiring inotropic support or\n             mechanical heart assistance).\n\n          -  Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to\n             stabilize heart failure.\n\n          -  Subject with significant pulmonary disease as determined and documented by the\n             Investigator.\n\n          -  Subject has significant chronic steroid use as determined and documented by the\n             Investigator.\n\n          -  Subject has a documented hypersensitivity or contraindication to anticoagulant or\n             antiplatelet medication.\n\n          -  Subject has renal insufficiency as evidenced by a serum creatinine greater than 3.0\n             mg/dL (265.5 \u00b5mol/L) or end-stage renal disease requiring chronic dialysis.\n\n          -  Subject has morbid obesity defined as a BMI greater than or equal to 40.\n\n          -  Subject has ongoing infection or sepsis.\n\n          -  Subject has blood dyscrasias (eg, leukopenia, acute anemia, thrombocytopenia, history\n             of bleeding diathesis, or coagulopathy).\n\n          -  Significant ascending aortic disease documented by diameter greater than 40mm.\n\n          -  Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within\n             90 days prior to the index procedure.\n\n          -  Subject is currently participating in another investigational drug or device study.\n\n          -  Subject requires emergency surgery for any reason.\n\n          -  Subject has a life expectancy less than 12 months.\n\n          -  Subject has other medical, social or psychological conditions that, in the opinion of\n             the Principal Investigator or the Subject Selection Committee, preclude the subject\n             from study participation.\n\n          -  Subject is diagnosed with dementia or admitted to a chronic care facility which would\n             fundamentally complicate rehabilitation from the procedure or compliance with\n             follow-up visits.\n\n          -  Subject has a documented allergy to contrast media, nitinol alloys, porcine tissue,\n             or bovine tissue."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02088021", 
            "org_study_id": "CL07045"
        }, 
        "intervention": {
            "arm_group_label": "Portico Transcatheter Aortic Valve Implantation", 
            "description": "Placement of the SJM Portico aortic valve with a ALC delivery system", 
            "intervention_name": "Portico Transcatheter Aortic Valve", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 12, 2014", 
        "number_of_arms": "1", 
        "overall_official": {
            "affiliation": "Herzzentrum Leipzig", 
            "last_name": "Axel Linke, Prof Dr. med", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Major Vascular Complications related to the Portico ALC Delivery System", 
                "safety_issue": "Yes", 
                "time_frame": "30 day post procedure"
            }, 
            {
                "measure": "All cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "30 day post procedure"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02088021"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Event rates as described by VARC-2\n\"Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document European Heart Journal (2012) 33, 2403-2418.\"", 
                "measure": "Event Rates", 
                "safety_issue": "Yes", 
                "time_frame": "30 days post procedure"
            }, 
            {
                "description": "Functional improvement from baseline as compared to 30 days by:\nNYHA Functional Classification\nSix Minute Walk Test\nEffective Orifice Area (EOA)", 
                "measure": "Functional improvement from baseline", 
                "safety_issue": "No", 
                "time_frame": "30 days post procedure"
            }, 
            {
                "description": "Acute device success defined as:\nAbility of the Portico ALC Delivery System to successfully deliver, deploy, and resheath (if necessary) a transcatheter aortic valve\nAbsence of procedural mortality\nCorrect positioning of a single prosthetic heart valve into the proper anatomical location\nIntended performance of the prosthetic heart valve, as defined by:\nmean aortic valve gradient <20 mmHg or peak velocity <3 m/s, and\nno moderate or severe prosthetic valve regurgitation", 
                "measure": "Acute device success", 
                "safety_issue": "No", 
                "time_frame": "12 months post procedure"
            }
        ], 
        "source": "St. Jude Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Jude Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014", 
        "why_stopped": "Business decision"
    }
}